Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes and Chronic Obstructive Pulmonary Disease: An Analysis From the Platelet Inhibition and Patient Outcomes (PLATO) Trial.
Andell P, James SK, Cannon CP, Cyr DD, Himmelmann A, Husted S, Keltai M, Koul S, Santoso A, Steg PG, Storey RF, Wallentin L, Erlinge D; PLATO Investigators. Andell P, et al. J Am Heart Assoc. 2015 Oct 9;4(10):e002490. doi: 10.1161/JAHA.115.002490. J Am Heart Assoc. 2015. PMID: 26452988 Free PMC article. Clinical Trial.
Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries.
Danchin N, Lettino M, Zeymer U, Widimsky P, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, Lopez Sendón J, Tousek P, Weidinger F, Weston CF, Zaman A, Andell P, Li J, Jukema JW; PIRAEUS group. Danchin N, et al. Among authors: andell p. Eur Heart J Cardiovasc Pharmacother. 2016 Jul;2(3):152-67. doi: 10.1093/ehjcvp/pvw003. Epub 2016 Jan 27. Eur Heart J Cardiovasc Pharmacother. 2016. PMID: 27533757
P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries.
Zeymer U, Widimsky P, Danchin N, Lettino M, Bardaji A, Barrabes JA, Cequier A, Claeys MJ, De Luca L, Dörler J, Erlinge D, Erne P, Goldstein P, Koul SM, Lemesle G, Lüscher TF, Matter CM, Montalescot G, Radovanovic D, Sendón JL, Tousek P, Weidinger F, Weston CF, Zaman A, Andell P, Li J, Jukema JW; PIRAEUS group. Zeymer U, et al. Among authors: andell p. Eur Heart J Cardiovasc Pharmacother. 2016 Oct;2(4):229-43. doi: 10.1093/ehjcvp/pvw005. Epub 2016 Mar 2. Eur Heart J Cardiovasc Pharmacother. 2016. PMID: 27533946
Cangrelor in combination with ticagrelor provides consistent and potent P2Y12-inhibition during and after primary percutaneous coronary intervention in real-world patients with ST-segment-elevation myocardial infarction.
Mohammad MA, Andell P, Koul S, James S, Scherstén F, Götberg M, Erlinge D. Mohammad MA, et al. Among authors: andell p. Platelets. 2017 Jun;28(4):414-416. doi: 10.1080/09537104.2016.1246714. Epub 2016 Nov 25. Platelets. 2017. PMID: 27885888
47 results